In the United Kingdom nine different slide tests and five different tube tests are marketed by 11 different enterprises. Of these enterprises Organon is the most important, next is Burroughs Wellcome, and Ortho UK takes the third place with a market share of about ... %, representing a turnover in 1978 of about £ ... As potential serious competitors can be named Hoffmann-La Roche (which has recently re-entered the UK market for laboratory pregnancy tests) and Mercia Diagnostics.
Total trade sales in the EEC of Gravindex pregnancy tests by the subsidiaries of Johnson & Johnson in the years 1973 to 1978 were: >PIC FILE= "T0013497">
C. Prices
Althought the active ingredients of the Gravindex pregnancy tests all come from Ortho Diagnostics (USA) and the subsidiaries such as Ortho UK and Cilag Alsbach only have to bottle and/or package them, there are big differences between the selling prices of Gravindex pregnancy tests throughout the common market. Prices are highest in Germany and lowest in the United Kingdom. In 1977 the Cilag-Alsbach price was 3 775 times the price charged by Ortho UK to dealers. Chart I shows the prices of Gravindex slide tests in the different Member States in the last six years and the differences between them.
Eurim Pharm imports Gravindex slide tests from the United Kingdom into Germany. It purchases these tests from various British chemists. In Germany Eurim Pharm sells the tests in the original packing together with the German registration number and instructions in German. Its selling prices are about 25 % lower than those of Cilag Alsbach, even after the goods have passed through the hands of an additional middle-man (the UK wholesaler or retailer).
Eurim Pharm's selling prices, and those of Ortho UK and Cilag Alsbach, are set out in Chart II. >PIC FILE= "T0013498">
>PIC FILE= "T0013499">
>PIC FILE= "T0013500">
D. Export prohibitions in the terms of trading for pharmaceutical dealers
Ortho UK
At least since 1 January 1973 and until January 1977, all the firm's "UK trade price lists" intended for sales to pharmaceutical dealers included, under "terms of trading", the following condition:
"Export prohibited except by prior arrangement".
(See for example the October 1975 price list.)
The corresponding (amended) condition in the January 1977 and all subsequent price lists reads as follows:
"Export prohibited to non-EEC countries except by prior arrangement".